Tracy Zimmerman, Ph.D. is currently the Chief Development Officer at Generation Bio, a biotechnology company developing genetic medicines. She arrived at Generation Bio in 2018 and has more than 20 years of drug development experience. Prior to joining Generation Bio, Tracy served as Senior Director, Research, at Alnylam Pharmaceuticals where she led cross-functional teams to advance the company’s early-stage RNAi pipeline from discovery through preclinical development and regulatory submission. Over her 15-year tenure at Alnylam, Tracy oversaw the integration of multiple facets of target and indication evaluation—including technical feasibility, target validation, unmet need, competitive landscape and market analysis—into recommendations for advancement of novel development candidates. She began her career at Variagenics, Inc. developing novel genotyping assays for evaluation of tumor-associated markers after completing a National Institutes of Health postdoctoral fellowship at Harvard Medical School/Dana-Farber Cancer Institute.
Tracy received her B.S. in biochemistry from Lehigh University and her Ph.D. in chemistry from the University of Colorado, Boulder.